---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-034761"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:22:16.943691+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences reprices executive stock options to $2.28

## Summary
- Compensation Committee approved repricing of 2018 Plan options to $2.28/share, the July 24 closing price.
- CEO John Fowler: 2,655,000 options repriced from $3.29-$22.85; CFO Marc Belsky: 765,000 options.
- CMO Noreen Roth Henig (980,000 options) and Strategic Advisor Christopher Kirk (832,500) included.
- Repricing excludes options under the 2015 Plan and 2022 Inducement Plan; all other terms unchanged.
- Purpose: retain key contributors and preserve cash without additional equity dilution.

## SEC filing metadata
- accession: 0000950170-23-034761
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023034761/0000950170-23-034761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023034761/kzr-20230724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-034761
- JSON: https://secwatch.observer/filing/0000950170-23-034761.json
- Plain text: https://secwatch.observer/filing/0000950170-23-034761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.